[
  {
    "idx": 1,
    "drug": "Tetracycline",
    "disease": "early lyme disease erythema migrans",
    "classification": "VALIDATED",
    "evidence": "Tetracycline was historically used for Lyme disease (erythema migrans). Now superseded by doxycycline, but still has clinical evidence from RCTs. IDSA 2020 guidelines recommend doxycycline/amoxicillin over tetracycline."
  },
  {
    "idx": 2,
    "drug": "Erythromycin",
    "disease": "early lyme disease erythema migrans",
    "classification": "PLAUSIBLE",
    "evidence": "Erythromycin shown inferior to tetracycline in Lyme RCTs (4/29 vs 0/39 progressed to late disease). Removed from recommended antibiotics due to poor tissue penetration. Has in vitro activity but clinical failure."
  },
  {
    "idx": 3,
    "drug": "Lovastatin",
    "disease": "familial hypercholesterolemia",
    "classification": "VALIDATED",
    "evidence": "FDA-approved for familial hypercholesterolemia. Multicenter trials show 17-39% LDL reduction. First statin ever approved (1987). Standard of care."
  },
  {
    "idx": 4,
    "drug": "Niacin",
    "disease": "dyslipidemia",
    "classification": "VALIDATED",
    "evidence": "FDA-approved for dyslipidemia (Niaspan, 1997). Reduces total cholesterol, LDL, TG and increases HDL. Combination with statins withdrawn by FDA (ACCORD/AIM-HIGH trials) but monotherapy still approved."
  },
  {
    "idx": 5,
    "drug": "Rosuvastatin",
    "disease": "dyslipidemia",
    "classification": "VALIDATED",
    "evidence": "Rosuvastatin is FDA-approved for dyslipidemia/hyperlipidemia. One of the most prescribed statins worldwide. Strong RCT evidence."
  },
  {
    "idx": 6,
    "drug": "Gemfibrozil",
    "disease": "hypercholesterolemia",
    "classification": "VALIDATED",
    "evidence": "FDA-approved for hypercholesterolemia. Helsinki Heart Study showed reduced coronary events. Less effective than statins for LDL but increases HDL."
  },
  {
    "idx": 7,
    "drug": "Niacin",
    "disease": "familial hypercholesterolemia",
    "classification": "VALIDATED",
    "evidence": "Niacin is used in familial hypercholesterolemia, especially in combination therapy. FDA-approved for hyperlipidemia."
  },
  {
    "idx": 8,
    "drug": "Rosuvastatin",
    "disease": "familial hypercholesterolemia",
    "classification": "VALIDATED",
    "evidence": "Rosuvastatin is FDA-approved and widely used for FH. One of the most potent statins for LDL reduction."
  },
  {
    "idx": 9,
    "drug": "Gemfibrozil",
    "disease": "familial hypercholesterolemia",
    "classification": "PLAUSIBLE",
    "evidence": "Gemfibrozil has been studied in FH (plasma lipoprotein changes), but is not first-line. Statins preferred. Used as adjunct for mixed dyslipidemia."
  },
  {
    "idx": 10,
    "drug": "Clopidogrel",
    "disease": "coronary artery disease",
    "classification": "VALIDATED",
    "evidence": "Clopidogrel is one of the most widely prescribed drugs for CAD. 2025 Lancet meta-analysis: superior to aspirin for secondary prevention. FDA-approved."
  },
  {
    "idx": 11,
    "drug": "Verapamil",
    "disease": "coronary artery disease",
    "classification": "VALIDATED",
    "evidence": "Verapamil FDA-approved for angina/coronary artery disease. INVEST trial showed equal prevention to atenolol. Reduces reinfarction 20-21%."
  },
  {
    "idx": 12,
    "drug": "Corticotropin",
    "disease": "autoimmune hepatitis",
    "classification": "PLAUSIBLE",
    "evidence": "Corticosteroids are first-line for autoimmune hepatitis (80-90% remission). ACTH stimulates cortisol production, so indirect mechanism plausible. But no specific ACTH/corticotropin trials for AIH found."
  },
  {
    "idx": 13,
    "drug": "Lovastatin",
    "disease": "hyperthyroidism",
    "classification": "PLAUSIBLE",
    "evidence": "2024 Mendelian randomization study suggests HMGCR inhibition (statin mechanism) is protective against hyperthyroidism via IGF-1 pathway. No clinical trials yet. Preclinical/genetic evidence only."
  },
  {
    "idx": 14,
    "drug": "Lovastatin",
    "disease": "atherosclerosis",
    "classification": "VALIDATED",
    "evidence": "Statins are the cornerstone of atherosclerosis treatment. Lovastatin FDA-approved for prevention/treatment of coronary heart disease and atherosclerotic disease progression."
  },
  {
    "idx": 15,
    "drug": "Pravastatin",
    "disease": "dyslipidemia",
    "classification": "VALIDATED",
    "evidence": "Pravastatin is FDA-approved for dyslipidemia. Multiple RCTs demonstrate efficacy (WOSCOPS, CARE, LIPID trials)."
  },
  {
    "idx": 16,
    "drug": "Methylprednisolone",
    "disease": "toxic epidermal necrolysis",
    "classification": "PLAUSIBLE",
    "evidence": "IV methylprednisolone pulse therapy used for TEN. Some case reports/case series show benefit. Systematic review: only 1/6 studies showed mortality benefit. Controversial - used in practice but evidence limited."
  },
  {
    "idx": 17,
    "drug": "Methylprednisolone",
    "disease": "pyoderma gangrenosum",
    "classification": "VALIDATED",
    "evidence": "Corticosteroids first-line for pyoderma gangrenosum. IV methylprednisolone pulse therapy (1g x 3-5 days) used for refractory cases. Published case series in JAMA Dermatology. Medscape lists as medication."
  },
  {
    "idx": 18,
    "drug": "Dexamethasone",
    "disease": "toxic epidermal necrolysis",
    "classification": "PLAUSIBLE",
    "evidence": "Systemic corticosteroids used for TEN but controversial. Limited evidence. Japanese guidelines include corticosteroid pulse therapy. Evidence base limited to retrospective studies."
  },
  {
    "idx": 19,
    "drug": "Prednisolone",
    "disease": "eosinophilic granulomatosis with polyangiitis",
    "classification": "VALIDATED",
    "evidence": "Corticosteroids are first-line treatment for EGPA (Churg-Strauss). Standard initial therapy: prednisone 1 mg/kg/day. Well-established in rheumatology guidelines."
  },
  {
    "idx": 20,
    "drug": "Methylprednisolone",
    "disease": "hidradenitis suppurativa",
    "classification": "PLAUSIBLE",
    "evidence": "Systemic corticosteroids used as rescue therapy for HS flares. Intermittent pulse dosing in guidelines. But not first-line - antibiotics and adalimumab preferred."
  },
  {
    "idx": 21,
    "drug": "Prednisolone",
    "disease": "lichen planus",
    "classification": "VALIDATED",
    "evidence": "Corticosteroids first-line for lichen planus (oral and cutaneous). Prednisolone/prednisone widely used. Cochrane review supports. JAMA Dermatology evidence analysis."
  },
  {
    "idx": 22,
    "drug": "Methylprednisolone",
    "disease": "polyarticular JIA",
    "classification": "VALIDATED",
    "evidence": "Corticosteroids used in JIA treatment (ACR 2011 guidelines). IV methylprednisolone pulse therapy for flares. Joint injections standard of care."
  },
  {
    "idx": 23,
    "drug": "Hydrocortisone",
    "disease": "lichen planus",
    "classification": "VALIDATED",
    "evidence": "Topical corticosteroids (including hydrocortisone) are first-line for lichen planus. Well-established treatment."
  },
  {
    "idx": 24,
    "drug": "Betamethasone",
    "disease": "choroiditis",
    "classification": "VALIDATED",
    "evidence": "Corticosteroids are the primary treatment for posterior uveitis/choroiditis. Periocular betamethasone injection is a standard route. Ophthalmic guidelines support this."
  },
  {
    "idx": 25,
    "drug": "Dexamethasone",
    "disease": "polyarticular JIA",
    "classification": "VALIDATED",
    "evidence": "Corticosteroids used in JIA. Dexamethasone used for systemic inflammation and as joint injection. ACR guidelines support."
  },
  {
    "idx": 26,
    "drug": "Lidocaine",
    "disease": "polyarticular JIA",
    "classification": "IMPLAUSIBLE",
    "evidence": "Lidocaine used as LOCAL ANESTHETIC during JIA joint injections (EMLA cream, subcutaneous), NOT as treatment for JIA itself. Model confuses procedural use with therapeutic indication."
  },
  {
    "idx": 27,
    "drug": "Prednisone",
    "disease": "temporal arteritis",
    "classification": "VALIDATED",
    "evidence": "Prednisone 40-60mg/day is THE first-line treatment for GCA/temporal arteritis. Universally accepted. Urgent treatment to prevent vision loss."
  },
  {
    "idx": 28,
    "drug": "Cortisone",
    "disease": "temporal arteritis",
    "classification": "PLAUSIBLE",
    "evidence": "Cortisone is a weaker corticosteroid. Prednisone preferred for GCA. Cortisone could work (same class) but not standard of care."
  },
  {
    "idx": 29,
    "drug": "Triamcinolone",
    "disease": "pyoderma gangrenosum",
    "classification": "VALIDATED",
    "evidence": "Intralesional triamcinolone injection is used for pyoderma gangrenosum. Topical/intralesional corticosteroids are first-line for mild/localized disease."
  },
  {
    "idx": 30,
    "drug": "Bupivacaine",
    "disease": "temporal arteritis",
    "classification": "IMPLAUSIBLE",
    "evidence": "Bupivacaine used as LOCAL ANESTHETIC during temporal artery BIOPSY procedure. Not a treatment for temporal arteritis itself. Model confuses diagnostic procedure with disease treatment."
  },
  {
    "idx": 31,
    "drug": "Erythromycin",
    "disease": "bacterial meningitis",
    "classification": "IMPLAUSIBLE",
    "evidence": "Erythromycin does NOT penetrate blood-brain barrier adequately. Not used for bacterial meningitis. Standard: ceftriaxone, vancomycin, ampicillin. Wrong antibiotic for this indication."
  },
  {
    "idx": 32,
    "drug": "Corticotropin",
    "disease": "polyarticular JIA",
    "classification": "PLAUSIBLE",
    "evidence": "ACTH (corticotropin) was historically used for inflammatory conditions. Modern practice uses synthetic corticosteroids instead. Mechanistically plausible but not current practice."
  },
  {
    "idx": 33,
    "drug": "Minocycline",
    "disease": "bacterial meningitis",
    "classification": "IMPLAUSIBLE",
    "evidence": "Minocycline has some CNS penetration but NOT used for bacterial meningitis. Not effective against common meningitis pathogens (N. meningitidis, S. pneumoniae, H. influenzae). Wrong indication."
  },
  {
    "idx": 34,
    "drug": "Mometasone",
    "disease": "chronic bronchitis",
    "classification": "PLAUSIBLE",
    "evidence": "Inhaled corticosteroids (ICS) used in COPD/chronic bronchitis with frequent exacerbations. Mometasone is an ICS but primarily marketed for asthma/allergic rhinitis. Off-label plausible."
  },
  {
    "idx": 35,
    "drug": "Fluticasone",
    "disease": "chronic bronchitis",
    "classification": "VALIDATED",
    "evidence": "Fluticasone (as Advair/Breo with LABA) is FDA-approved for COPD which includes chronic bronchitis. Well-established in guidelines (GOLD)."
  },
  {
    "idx": 36,
    "drug": "Azathioprine",
    "disease": "polyarticular JIA",
    "classification": "PLAUSIBLE",
    "evidence": "Azathioprine used as steroid-sparing agent in some autoimmune conditions. Used in some JIA cases but not first-line (methotrexate preferred). ACR guidelines mention as option."
  },
  {
    "idx": 37,
    "drug": "Ofloxacin",
    "disease": "sinusitis",
    "classification": "VALIDATED",
    "evidence": "Ofloxacin has clinical trial evidence for sinusitis (93.7% cure rate). Fluoroquinolone class effective. Superseded by levofloxacin (more potent isomer) but itself validated."
  },
  {
    "idx": 38,
    "drug": "Doxycycline",
    "disease": "Pseudomonas respiratory infection in CF",
    "classification": "IMPLAUSIBLE",
    "evidence": "Pseudomonas aeruginosa is inherently RESISTANT to doxycycline. Standard: tobramycin, ceftazidime, ciprofloxacin. Doxycycline has anti-inflammatory effects in CF but NOT antipseudomonal. Wrong drug for Pseudomonas."
  },
  {
    "idx": 39,
    "drug": "Levofloxacin",
    "disease": "sinusitis",
    "classification": "VALIDATED",
    "evidence": "Levofloxacin FDA-approved for acute bacterial sinusitis. Multiple RCTs. Respiratory fluoroquinolone with excellent sinus penetration."
  },
  {
    "idx": 40,
    "drug": "Liothyronine",
    "disease": "congenital hypothyroidism",
    "classification": "PLAUSIBLE",
    "evidence": "Liothyronine FDA-approved for hypothyroidism broadly. Used in congenital hypothyroidism with central resistance or persistent hyperthyrotropinemia. Not first-line (levothyroxine preferred) but has specific applications."
  },
  {
    "idx": 41,
    "drug": "Verapamil",
    "disease": "acute coronary syndrome",
    "classification": "PLAUSIBLE",
    "evidence": "Verapamil reduces reinfarction in post-MI patients without HF. But NOT first-line for ACS (beta-blockers, antiplatelet, anticoagulant preferred). Contraindicated with HF. Specialist use only."
  },
  {
    "idx": 42,
    "drug": "Propranolol",
    "disease": "coronary artery disease",
    "classification": "VALIDATED",
    "evidence": "Propranolol FDA-approved for angina and post-MI prevention. Reduces mortality 20% in post-MI trials. Beta-blockers are standard for CAD management."
  },
  {
    "idx": 43,
    "drug": "Enoxaparin",
    "disease": "acute coronary syndrome",
    "classification": "VALIDATED",
    "evidence": "Enoxaparin FDA-approved for ACS (unstable angina/NSTEMI). ESSENCE and TIMI 11B trials. Superior to UFH. AHA/ACC guideline recommended."
  },
  {
    "idx": 44,
    "drug": "Lovastatin",
    "disease": "type 2 diabetes mellitus",
    "classification": "IMPLAUSIBLE",
    "evidence": "Statins may INCREASE diabetes risk (Lancet 2024 meta-analysis). Lovastatin is lower risk than rosuvastatin but still associated with new-onset diabetes. Some MR evidence for glucose-lowering but contradicted by RCT data. Not a diabetes treatment."
  },
  {
    "idx": 45,
    "drug": "Esmolol",
    "disease": "stable angina",
    "classification": "PLAUSIBLE",
    "evidence": "Esmolol shown effective in UNSTABLE angina (RCT: fewer clinical events vs placebo). IV-only beta-blocker, not practical for chronic stable angina. Oral beta-blockers preferred for stable angina."
  },
  {
    "idx": 46,
    "drug": "Ibutilide",
    "disease": "tachyarrhythmia",
    "classification": "VALIDATED",
    "evidence": "Ibutilide FDA-approved (1995) for acute conversion of atrial flutter/fibrillation. 55-61% success rate within 90 min. Class III antiarrhythmic. Tachyarrhythmia is the correct indication."
  },
  {
    "idx": 47,
    "drug": "Prasugrel",
    "disease": "coronary artery disease",
    "classification": "VALIDATED",
    "evidence": "Prasugrel FDA-approved for ACS with PCI. TRITON-TIMI 38: reduced ischemic events vs clopidogrel. Standard antiplatelet for CAD with stenting."
  },
  {
    "idx": 48,
    "drug": "Sitafloxacin",
    "disease": "complicated UTI",
    "classification": "VALIDATED",
    "evidence": "Multiple RCTs: 97% clinical cure rate. Non-inferior to levofloxacin and ceftriaxone. Approved in Japan/Thailand. Strong evidence base."
  },
  {
    "idx": 49,
    "drug": "Moxifloxacin",
    "disease": "bronchiectasis",
    "classification": "PLAUSIBLE",
    "evidence": "Moxifloxacin effective for acute exacerbations of chronic bronchitis/COPD (RCTs). For bronchiectasis specifically, limited direct evidence but same respiratory pathogens. Guideline-supported for exacerbations."
  },
  {
    "idx": 50,
    "drug": "Ciprofloxacin",
    "disease": "bronchiectasis",
    "classification": "VALIDATED",
    "evidence": "Ciprofloxacin is used for bronchiectasis exacerbations. Inhaled ciprofloxacin studied in clinical trials for chronic bronchiectasis management. Guideline-supported."
  }
]